Genmab — Februar 2021
-
Så Genmab indregner kun 90 % som omsætning i regnskabsåret 2020? Bliver de resterende 10 % indregnet som en forudbetaling?
-
AbbVie to pay Genmab an upfront payment of USD 750 million with total potential milestone payments of up to USD 3.15 billion
-
Jeg tænker, at vi ser de 750m indregnet med det samme
-
-
Det er helt normal praksis at indregne upfront betaling over det antal år forskningsaftalen løber. For husk der også var sådan et element. Og der fik de altså $75 mio upfront for den del
-
Det var så 90 % i 2020. Godt spottet Doublo
-
We expect our 2020 revenue to be in the range of DKK 9,100 - DKK 9,500 million, an increase of DKK 4,350 million compared to our previous guidance. The increase is due to nearly 90% of the USD 750 million upfront payment from this agreement being recognized immediately with the remainder being recognized over a number of years.
-
My bad. Sorry
-
Volumen har været lidt til den svage side - mon ikke det har været bedre alternative investeringer, der har drevet udviklingen?
-
Næh - jeg siger, at der er bedre alternative investeringer
-
Det er mit bud - og tilsat et lille krydderi af usikkerhed i form af en voldgift, så rykker de stigende renter i opfattelsen af casen
-
Tænker du på de renteindtægter man får af at gå fra 0,00% til 0,0%?
-
@Stockbull: Vi nærmer os din triangel-prognose på 2390. Vil du mene vi skal op herfra? siger TA noget om det?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind